Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PADLINK-005 in previously treated PD-L1 positive non-small-cell lung cancer
2025-521281-97-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Dec 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing PF-08046054/SGN-PDL1V with Docetaxel (2 arms). Primary endpoint: Overall survival. Planned start Dec 2025; status: authorised.
02
Drugs
SGN-PDL1Vdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-521281-97-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521281-97-00.